Trump Reportedly Plans to Dismiss FDA Commissioner Marty Makary
President Donald Trump is reportedly preparing to fire FDA Commissioner Marty Makary, according to a report by the Wall Street Journal, which cites sources familiar with his plans. Makary’s potential departure would mark the end of a contentious tenure for the former Johns Hopkins surgeon, who became a polarizing figure due to his outspoken views on health policies during the COVID-19 pandemic.
Makary’s Controversial Stance on Vaccination Mandates
Makary first gained attention for his criticism of vaccination mandates, opposing measures such as the use of masks by children to curb the virus’s spread. His views often placed him at odds with mainstream public health recommendations, creating friction within the FDA and with the Trump administration.
While Trump’s plan to dismiss Makary is reportedly ongoing, there is a possibility that the president might change his mind, as noted by the Wall Street Journal. The evolving nature of this decision underscores the political dynamics at play within the administration.
Tensions Over E-Cigarette Policies
Makary recently faced criticism from Trump for his stance against fruit-flavored e-cigarettes. This dispute came to a head when the FDA approved 45 types of e-cigarettes, a decision that highlighted the ongoing debates over vaping regulations.
Since his confirmation last March, Makary has navigated an agency plagued by significant challenges, including layoffs and high turnover rates. His 14-month tenure has been marked by a revolving door of leadership, impacting the FDA’s ability to function effectively.
Leadership Changes and Political Influence
The departure of key figures, such as Richard Pazdur, MD, the former longtime oncology chief who resigned after just a month as director of the Center for Drug Evaluation and Research (CDER), has drawn attention to the loss of expertise within the agency. Pazdur’s comments about political influences interfering with regulatory decision-making have raised concerns about the FDA’s objectivity and independence.
Additionally, the resignation of Vinay Prasad, MD, as director of the Center for Biologics Evaluation and Research (CBER)—his second in eight months—has further underscored the instability within the FDA. Prasad’s departure amid controversies over cell and gene therapies for rare diseases highlights the challenges facing the agency.
Criticism and Scrutiny
Makary has faced criticism regarding the FDA’s inconsistent drug testing protocols and policies related to abortion. Last November, the agency faced a significant backlash when hundreds of industry leaders signed a letter urging Makary to ensure more predictability and questioning the FDA’s operational capabilities.
Recently, the FDA came under increased scrutiny for blocking the release of studies on COVID and shingles vaccines, which found that side effects from the shots were “very rare,” as reported by the New York Times. This decision has fueled debates over transparency and public trust in the agency’s decisions.
The Department of Health and Human Services has not immediately responded to requests for comment on these developments.
For further details, please refer to the original report Here.
“`
